Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AgeX Therapeutics Inc | AGE | AMEX | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 11.10 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.10 | 11.10 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.31 - 22.32 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 11.10 | USD |
AgeX Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 348.77M | 37.95M | - | 142k | -14.8M | -0.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AgeX Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/22/2024 | 16:27 | GlobeNewswire Inc. | AgeX Therapeutics Reports Fourth Quarter and Annual 2023.. |
| 3/07/2024 | 15:49 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business.. |
| 3/07/2024 | 15:47 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/07/2024 | 06:47 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 2/14/2024 | 15:01 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 2/13/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 2/06/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/05/2024 | 06:19 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 1/19/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/17/2024 | 15:19 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of.. |
| 1/16/2024 | 08:11 | Edgar (US Regulatory) | Form S-4/A - Registration of securities, business.. |
| 1/11/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.41 | 22.32 | 0.34 | 0.8791518 | 95,826 | 10.69 | 2,607.32% |
| 6 Months | 0.621 | 22.32 | 0.31 | 0.5004045 | 192,942 | 10.48 | 1,687.44% |
| 1 Year | 0.60 | 22.32 | 0.31 | 0.523985 | 100,152 | 10.50 | 1,750.00% |
| 3 Years | 1.59 | 22.32 | 0.31 | 0.8739307 | 113,548 | 9.51 | 598.11% |
| 5 Years | 4.79 | 22.32 | 0.31 | 2.05 | 438,181 | 6.31 | 131.73% |
AgeX Therapeutics Description
| AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547. |
